Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
A Phase I/II, Open Label, Study to Evaluate Safety, Tolerability and Efficacy of Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
Dana-Farber Cancer Institute
49 participants
Nov 1, 2024
INTERVENTIONAL
Conditions
Summary
This study will evaluate the safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Elranatamab administered subcutaneously for 6 cycles of treatment with 28 days in a treatment cycle
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06569147